A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verona Pharma PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 16,100 shares of VRNA stock, worth $624,841. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,100
Previous 140,100 88.51%
Holding current value
$624,841
Previous $2.03 Million 77.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.46 - $30.16 $16.6 Million - $32.4 Million
1,075,407 Added 1048.0%
1,178,022 $33.9 Million
Q2 2024

Aug 14, 2024

SELL
$11.48 - $17.02 $454,573 - $673,940
-39,597 Reduced 27.84%
102,615 $1.48 Million
Q1 2024

May 15, 2024

BUY
$15.3 - $20.24 $1.74 Million - $2.31 Million
114,022 Added 404.48%
142,212 $2.29 Million
Q4 2023

Feb 14, 2024

SELL
$11.94 - $20.47 $1.77 Million - $3.04 Million
-148,293 Reduced 84.03%
28,190 $560,000
Q3 2023

Nov 14, 2023

SELL
$16.3 - $22.09 $1.78 Million - $2.42 Million
-109,383 Reduced 38.26%
176,483 $2.88 Million
Q2 2023

Aug 14, 2023

BUY
$19.41 - $23.43 $341,965 - $412,789
17,618 Added 6.57%
285,866 $6.04 Million
Q1 2023

May 15, 2023

BUY
$18.06 - $25.27 $4.84 Million - $6.78 Million
268,248 New
268,248 $5.39 Million
Q3 2022

Nov 14, 2022

BUY
$4.14 - $13.59 $2.83 Million - $9.3 Million
684,511 Added 6368.14%
695,260 $7.11 Million
Q2 2022

Aug 15, 2022

SELL
$3.55 - $5.06 $4,047 - $5,768
-1,140 Reduced 9.59%
10,749 $45,000
Q4 2021

Feb 14, 2022

SELL
$3.91 - $7.08 $42,935 - $77,745
-10,981 Reduced 48.01%
11,889 $79,000
Q3 2021

Nov 15, 2021

BUY
$5.29 - $6.35 $120,982 - $145,224
22,870 New
22,870 $125,000
Q2 2019

Aug 14, 2019

SELL
$5.1 - $6.91 $55,202 - $74,793
-10,824 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$5.52 - $10.0 $59,748 - $108,240
10,824 New
10,824 $0

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.37B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.